Article
Empirical ways to identify novel Bedaquiline resistance mutations in AtpE
29 May 2019
Abstract excerpt
Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a novel mechanism of action in over 40 years, has already been detected in Mycobacterium tuberculosis. As a new drug, however, there is currently insufficient clinical data to facilitate reliable and timely identification of genomic determinants of resistance. Here we investigate the structural basis for M. tuberculosis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.